Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Harbor BioSciences Sells China Rights for Three Prospective Drugs to CIPI

publication date: Jan 18, 2011
Harbor BioSciences, Inc. of San Diego has out-licensed the China rights for three products to the China State Institute of Pharmaceutical Industry (CIPI). CIPI is a subsidiary of the China National Pharmaceutical Group Corporation (Sinopharm). Two of the products are undergoing clinical trials, while the third is in pre-clinical development. Their targets are type 2 diabetes, prostate cancer, inflammation and infectious diseases. More details....

Stock Symbol: (OTCBB: HRBR)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital